Tuesday, August 30, 2016

BRIEF-Kamada meets primary endpoint of U.S. Phase 2 study of inhaled Alpha-1 Antitrypsin

* Kamada meets primary endpoint of U.S. Phase 2 study of

inhaled Alpha-1 Antitrypsin for the treatment of Alpha-1

Antitrypsin deficiency

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)